Product Information
DIAZEPAM 10 MG RECTAL GEL SYRG is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $208.7128 per EA under NDC 43386028002. Its NADAC has been published 138 times since Feb 14, 2024.
FDA first approved this application on May 30, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/2g
Manufacturer
Lupin Pharmaceuticals Inc.NDC
43386028002
Classification
Generic
Dosage Form
GEL
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
DIAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA091076FDA Approved
5/30/2023
TE Code
AB
On Market Since
10/30/2023
Pharmacological Classes
Price Statistics
The NADAC for DIAZEPAM 10 MG RECTAL GEL SYRG has been published 138 times since Feb 14, 2024, and over the history we have for it it has declined 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $208.7128 per EA |
|---|---|
| All-time high | $277.6770 (Oct 16, 2024) |
| All-time low | $187.4787 (Apr 22, 2026) |
| 52-week high | $261.0661 |
| 52-week low | $187.4787 |
| Median price | $250.7084 |
| Average price | $236.3398 |
| Largest weekly change | +30.3% (Aug 21, 2024) |
| Weeks tracked | 138 |
| Tracking since | Feb 14, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Diazepam market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DIAZEPAM 10 MG RECTAL GEL SYRG?
The current National Average Drug Acquisition Cost (NADAC) for DIAZEPAM 10 MG RECTAL GEL SYRG, manufactured by Lupin Pharmaceuticals Inc., is $208.7128 per EA (NDC 43386028002), effective Sep 30, 2026.
How has the price of DIAZEPAM 10 MG RECTAL GEL SYRG changed over time?
Over the history we have for it, the NADAC for DIAZEPAM 10 MG RECTAL GEL SYRG has declined 17.7%. It has been tracked across 138 weekly CMS publications since Feb 14, 2024.
What are the highest and lowest recorded NADAC prices for DIAZEPAM 10 MG RECTAL GEL SYRG?
Since Feb 14, 2024, the NADAC for DIAZEPAM 10 MG RECTAL GEL SYRG has ranged from a low of $187.4787 (Apr 22, 2026) to a high of $277.6770 (Oct 16, 2024), with a median of $250.7084 per EA.
Are there cheaper alternatives to DIAZEPAM 10 MG RECTAL GEL SYRG?
No other NADAC-published product currently shares the active ingredient and strength of DIAZEPAM 10 MG RECTAL GEL SYRG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DIAZEPAM 10 MG RECTAL GEL SYRG?
DIAZEPAM 10 MG RECTAL GEL SYRG (NDC 43386028002) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.